NEW YORK, Oct. 17, 2019 /PRNewswire/ -- Renalytix AI plc
(AIM: RENX), a developer of artificial intelligence enabled
clinical diagnostics for kidney disease, announces that Capital
District Physicians' Health Plan, Inc. (CDPHP®), a
physician led health insurance provider, has adopted coverage
determination policies that will provide KidneyIntelX™ for
qualified CDPHP members who have Type 2 diabetes and chronic kidney
disease (diabetic kidney disease or "DKD"). In the United States, approximately 12 million
people currently have diabetic kidney disease.1
Qualified CDPHP members are eligible for KidneyIntelX testing and
score reporting for the risk of rapid progression of kidney
disease.
A coverage determination policy is a determination of whether
and under what circumstances a payor will pay for an item or
service. Insurance coverage is typically limited to items or
services that are considered by the payor as 'reasonable and
necessary' for the diagnosis or treatment of an illness or injury.
KidneyIntelX is designed to improve risk stratification and
clinical management of patients with DKD in an effort to improve
patient outcomes and health care system economics. KidneyIntelX
uses machine-learning algorithms to assess a combination of
predictive blood-based biomarkers and features from a patient's
electronic health record. The list price for KidneyIntelX is
$970 per reportable result.
"At CDPHP, we have been on a mission to support our members with
diabetes to the best of our ability, offering programming and
services to meet their lifestyle choices and needs," said
John D. Bennett, MD, President and
CEO of CDPHP. "Coverage of KidneyIntelX for qualified members is a
proactive step toward identifying and treating fast-progressing
kidney disease."
"This CDPHP coverage determination is an important milestone for
opening market access to the predictive value and data assessment
capacity of KidneyIntelX in this critical medical indication," said
James McCullough, Chief Executive
Officer of RenalytixAI. "CDPHP is a progressive thinking physician
led payor group that is offering advanced technology solutions to
help patients experiencing rapid kidney function decline to slow or
prevent the devastating effects of end-stage renal disease and
dialysis."
One of the greatest drivers of health care cost today is
patients whose kidney disease is not diagnosed in time and face
kidney failure and unplanned transition to dialysis. Each year
kidney disease kills more people than breast and prostate
cancer2.
In a recent study published April
1 20193, DKD patients who scored high-risk
by KidneyIntelX were 10 times more likely to experience kidney
failure than those who scored low-risk. For patients
experiencing rapid progression of kidney disease and therefore most
likely to advance toward end-stage renal disease and dialysis,
there are several clinical management strategies and proven
therapeutic options to slow the rate of disease progression and/or
halt its progress.
Notably in the same study, greater than 95% of patients with a
low KidneyIntelX™ score did not experience any progression
of their kidney disease over the next 5 years. As a result, even
though these patients have known diabetic kidney disease, they are
unlikely to progress with their disease further and can remain at a
primary care physician level for monitoring.
About Kidney Disease
Kidney disease is now recognized
as a public health epidemic affecting over 850 million people
globally. The Centers for Disease Control estimates there that 15%
of United States adults or 37
million people currently have kidney disease. It is reported that 9
out of 10 adults with chronic kidney disease do not know they have
it and 1 out of 2 people with very low kidney function who are not
on dialysis do not know they have CKD.4 Kidney disease
is referred to as a "silent killer" because it often has no
symptoms and can go undetected until a very advanced stage. Each
year kidney disease kills more people than breast and prostate
cancer. Every day 13 patients die in the
United States while waiting for a kidney transplant.
About CDPHP®
Established in 1984, CDPHP is
a physician-founded, member-focused and community-based
not-for-profit health plan that offers high-quality affordable
health insurance plans to members in 26 counties throughout
New York. For more information
visit www.cdphp.com. CDPHP is also on Facebook, Twitter, LinkedIn,
and Instagram.
About RenalytixAI
RenalytixAI is a developer of
artificial intelligence-enabled clinical in vitro diagnostic
solutions for kidney disease, one of the most common and costly
chronic medical conditions globally. The Company's products are
being designed to make significant improvements in kidney disease
diagnosis, transplant management, clinical care, patient
stratification for drug clinical trials, and drug target discovery.
For more information, visit renalytixai.com.
1
https://www.niddk.nih.gov/health-information/health-statistics/kidney-disease
2 https://www.ncbi.nlm.nih.gov/pubmed/30738630
3 https://www.biorxiv.org/content/10.1101/587774v1
4
https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html
View original
content:http://www.prnewswire.com/news-releases/renalytixai-partners-with-capital-district-physicians-health-plan-inc-on-kidneyintelx-300940287.html
SOURCE RenalytixAI